Camber Capital Management’s AnaptysBio ANAB Stock Holding History

Camber Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.77M	Sell	125,000 -625,000	-83%	-$13.1M	0.26%	24
2025 Q1	$13.9M	Sell	750,000 -500,000	-40%	-$8.34M	0.5%	26
2024 Q4	$16.6M	Buy	+1,250,000	New	+$30.3M	0.38%	33
2024 Q3	–	Sell	-500,000	Closed	-$12.5M	–	34
2024 Q2	$12.5M	Buy	+500,000	New	+$11.6M	0.35%	31

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Camber Capital Management's ANAB Position: Q2 2025 in Review

Camber Capital Management reduced its AnaptysBio (ANAB) stake by 83% in Q2 2025, selling an estimated $13.1M and leaving 125,000 shares worth $2.77M. The position accounts for 0.26% of the portfolio, ranked #24.

Camber Capital Management first reported a position in ANAB in Q2 2024 and has held it in 4 quarters since. The position peaked at $16.6M in Q4 2024. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Camber Capital Management held 125,000 shares of AnaptysBio worth $2.77M as of Q2 2025.
Camber Capital Management sold 625,000 AnaptysBio shares in Q2 2025, an estimated $13.1M.
AnaptysBio made up 0.26% of Camber Capital Management's portfolio in Q2 2025, its #24 holding.
Camber Capital Management first reported a position in AnaptysBio in Q2 2024 and has held it in 4 quarters since.
Camber Capital Management's AnaptysBio position peaked at $16.6M in Q4 2024.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.